Comparative proteomics and pulmonary toxicity of instilled single-walled carbon nanotubes, crocidolite asbestos, and ultrafine carbon black in mice.

Publisher: Oxford University Press Country of Publication: United States NLM ID: 9805461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0929 (Electronic) Linking ISSN: 10960929 NLM ISO Abbreviation: Toxicol Sci Subsets: MEDLINE

Publication: 1999- : Cary, NC : Oxford University Press
Original Publication: Orlando, FL : Academic Press, c1998-

Asbestos, Crocidolite/*toxicity ; Lung/*drug effects ; Nanotubes, Carbon/*toxicity ; Proteome/*metabolism ; Proteomics/*methods ; Soot/*toxicity; Animals ; Bronchoalveolar Lavage Fluid/chemistry ; Bronchoalveolar Lavage Fluid/cytology ; Bronchoalveolar Lavage Fluid/immunology ; Chromatography, High Pressure Liquid ; Cytokines/immunology ; Female ; Instillation, Drug ; Lung/metabolism ; Lung/pathology ; Mice ; Mice, Inbred C57BL ; Particle Size ; Peptides/metabolism ; Pneumonia/chemically induced ; Pneumonia/immunology ; Pneumonia/metabolism ; Pneumonia/pathology ; Proteins/metabolism ; Pulmonary Fibrosis/chemically induced ; Pulmonary Fibrosis/immunology ; Pulmonary Fibrosis/metabolism ; Pulmonary Fibrosis/pathology ; Tandem Mass Spectrometry

Reflecting their exceptional potential to advance a range of biomedical, aeronautic, and other industrial products, carbon nanotube (CNT) production and the potential for human exposure to aerosolized CNTs are increasing. CNTs have toxicologically significant structural and chemical similarities to asbestos (AB) and have repeatedly been shown to cause pulmonary inflammation, granuloma formation, and fibrosis after inhalation/instillation/aspiration exposure in rodents, a pattern of effects similar to those observed following exposure to AB. To determine the degree to which responses to single-walled CNTs (SWCNT) and AB are similar or different, the pulmonary response of C57BL/6 mice to repeated exposures to SWCNTs, crocidolite AB, and ultrafine carbon black (UFCB) were compared using high-throughput global high performance liquid chromatography fourier transform ion cyclotron resonance mass spectrometry (HPLC-FTICR-MS) proteomics, histopathology, and bronchoalveolar lavage cytokine analyses. Mice were exposed to material suspensions (40 micrograms per mouse) twice a week for 3 weeks by pharyngeal aspiration. Histologically, the incidence and severity of inflammatory and fibrotic responses were greatest in mice treated with SWCNTs. SWCNT treatment affected the greatest changes in abundance of identified lung tissue proteins. The trend in number of proteins affected (SWCNT [376] > AB [231] > UFCB [184]) followed the potency of these materials in three biochemical assays of inflammation (cytokines). SWCNT treatment uniquely affected the abundance of 109 proteins, but these proteins largely represent cellular processes affected by AB treatment as well, further evidence of broad similarity in the tissue-level response to AB and SWCNTs. Two high-sensitivity markers of inflammation, one (S100a9) observed in humans exposed to AB, were found and may be promising biomarkers of human response to SWCNT exposure.

Circ Res. 2006 Mar 3;98(4):453-62. (PMID: 16514078)
J Am Soc Mass Spectrom. 2002 Feb;13(2):144-54. (PMID: 11838018)
Crit Rev Clin Lab Sci. 2008;45(6):531-62. (PMID: 19003601)
Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L698-708. (PMID: 15951334)
Proteomics. 2007 Dec;7(23):4388-97. (PMID: 17963277)
J Proteome Res. 2008 Jun;7(6):2406-14. (PMID: 18422355)
Toxicol Sci. 2009 Dec;112(2):468-81. (PMID: 19584127)
J Toxicol Sci. 2008 Aug;33(3):385; author reply 386-8. (PMID: 18670173)
Toxicol Appl Pharmacol. 2010 Feb 1;242(3):256-62. (PMID: 19874835)
Environ Toxicol. 2008 Feb;23(1):110-6. (PMID: 18214922)
Chem Res Toxicol. 2008 Sep;21(9):1698-705. (PMID: 18636756)
J Toxicol Environ Health A. 2010;73(5):378-95. (PMID: 20155580)
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 15;864(1-2):95-101. (PMID: 18313996)
J Proteome Res. 2009 Feb;8(2):860-9. (PMID: 19105609)
Chem Rev. 2007 Aug;107(8):3621-53. (PMID: 17649984)
J Appl Physiol (1985). 1994 Sep;77(3):1060-6. (PMID: 7836104)
Curr Top Microbiol Immunol. 2005;291:91-111. (PMID: 15981461)
J Proteome Res. 2010 Nov 5;9(11):5748-56. (PMID: 20831241)
Toxicol Appl Pharmacol. 2007 Jun 15;221(3):339-48. (PMID: 17482224)
Trends Immunol. 2005 Jul;26(7):388-95. (PMID: 15922663)
J Proteome Res. 2002 May-Jun;1(3):233-7. (PMID: 12645900)
Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L552-65. (PMID: 18658273)
Nano Lett. 2008 Feb;8(2):437-45. (PMID: 18225938)
J Toxicol Environ Health A. 2004 Jan 9;67(1):87-107. (PMID: 14668113)
Bioinformatics. 2007 Aug 1;23(15):2021-3. (PMID: 17545182)
Environ Health Perspect. 2007 May;115(5):756-63. (PMID: 17520064)
Science. 2002 Aug 2;297(5582):787-92. (PMID: 12161643)
Clin Nutr. 2009 Jun;28(3):291-8. (PMID: 19346035)
BMC Bioinformatics. 2009 Mar 17;10:87. (PMID: 19292916)
Amino Acids. 2011 Oct;41(4):821-42. (PMID: 20213444)
Am J Respir Cell Mol Biol. 2008 May;38(5):579-90. (PMID: 18096873)
J Leukoc Biol. 2009 Sep;86(3):577-87. (PMID: 19237640)
Toxicol Sci. 2004 Jan;77(1):117-25. (PMID: 14514968)
Methods Mol Biol. 2004;264:161-72. (PMID: 15020788)
Toxicol Appl Pharmacol. 2005 Sep 15;207(3):221-31. (PMID: 16129115)
J Biol Chem. 2001 Nov 9;276(45):41969-76. (PMID: 11553626)
Bioinformatics. 2007 Apr 1;23(7):906-9. (PMID: 17324940)
J Immunol. 2001 Mar 1;166(5):3362-8. (PMID: 11207292)
Proteomics. 2002 May;2(5):513-23. (PMID: 11987125)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Sep-Oct;1(5):511-29. (PMID: 20049814)
Proteomics. 2006 Jul;6(13):3949-57. (PMID: 16767788)
Bioinformatics. 2008 Jul 1;24(13):1556-8. (PMID: 18453552)
Bioinformatics. 2006 May 15;22(10):1278-9. (PMID: 16595561)
Mass Spectrom Rev. 2006 May-Jun;25(3):450-82. (PMID: 16429408)
Proc Am Thorac Soc. 2007 Jul;4(3):252-7. (PMID: 17607008)
Toxicol Sci. 2004 Jan;77(1):126-34. (PMID: 14514958)
Toxicol Sci. 2010 Jan;113(1):226-42. (PMID: 19822600)
J Toxicol Environ Health A. 2003 Aug 8;66(15):1441-52. (PMID: 12857634)
Thromb Haemost. 2007 Aug;98(2):262-73. (PMID: 17721605)
Toxicol Appl Pharmacol. 2008 Sep 1;231(2):235-40. (PMID: 18534653)

U19 ES019544 United States ES NIEHS NIH HHS

0 (Cytokines)
0 (Nanotubes, Carbon)
0 (Peptides)
0 (Proteins)
0 (Proteome)
0 (Soot)
12001-28-4 (Asbestos, Crocidolite)

Date Created: 20101208 Date Completed: 20110617 Latest Revision: 20211020

20231215

PMC3044201

10.1093/toxsci/kfq363

21135415